Overview

Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia

Status:
COMPLETED

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

Summary

Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide

Phase:

PHASE1

Details

Lead Sponsor:

SDK Therapeutics, Inc.

Collaborator:

The University of Hong Kong

Treatments:

Arsenic Trioxide